PLN-101095 在成人晚期或转移性实体瘤中的 1 期研究
一项 1a/1b 期多中心、开放标签剂量递增/扩展研究,旨在评估 PLN-101095 单药治疗以及与 Pembrolizumab 联合治疗晚期或转移性实体瘤成人受试者的安全性、耐受性、药代动力学和抗肿瘤活性的初步证据服用派姆单抗期间疾病进展的人
This is a Phase 1a/1b, dose-escalation/expansion, consecutive-cohort, open-label study to evaluate the safety, tolerability, PK, PD, and preliminary evidence of antitumor activity of PLN-101095 in combination with pembrolizumab (the study treatment regimen) in adult participants with advanced or metastatic solid tumors for which pembrolizumab is indicated but have documented disease progression (refractory [primary resistance]) or relapsed [secondary resistance]) after at least 3 months from the start of treatment with pembrolizumab.
The study will consist of 2 main parts:
- Part 1: Consecutive dose-escalation cohorts using a Bayesian optimal interval (BOIN) dose escalation design with accelerated titration
- Part 2: Dose-expansion cohorts using Simon's 2-stage design
研究概览
地位
条件
研究类型
注册 (估计的)
阶段
- 阶段1
联系人和位置
学习联系方式
- 姓名:Pliant Therapeutics Medical Monitor
- 电话号码:clintrials@pliantrx.com
- 邮箱:clintrials@pliantrx.com
学习地点
-
-
Connecticut
-
New Haven、Connecticut、美国、06511
- 完全的
- Yale University
-
-
District of Columbia
-
Washington D.C.、District of Columbia、美国、20007
- 招聘中
- Georgetown University Medical Center
-
接触:
- Pliant Therapeutics Medical Monitor
- 邮箱:clintrials@pliantrx.com
-
-
Georgia
-
Atlanta、Georgia、美国、30322
- 招聘中
- Winship Cancer Institute of Emory University
-
接触:
- Pliant Therapeutics Medical Monitor
- 邮箱:clintrials@pliantrx.com
-
-
Michigan
-
Grand Rapids、Michigan、美国、49546
- 招聘中
- South Texas Accelerated Research Therapeutics (START)
-
接触:
- Pliant Therapeutics Medical Monitor
- 邮箱:clintrials@pliantrx.com
-
-
Missouri
-
St Louis、Missouri、美国、63110
- 招聘中
- Washington University Medicine
-
接触:
- Pliant Therapeutics Medical Monitor
- 邮箱:clintrials@pliantrx.com
-
-
New Jersey
-
East Brunswick、New Jersey、美国、08816
- 招聘中
- START New Jersey
-
接触:
- Pliant Therapeutics Medical Monitor
- 邮箱:clintrials@pliantrx.com
-
New Brunswick、New Jersey、美国、08901
- 招聘中
- Rutgers Cancer Institute of New Jersey
-
接触:
- Pliant Therapeutics Medical Monitor
- 邮箱:clintrials@pliantrx.com
-
-
New York
-
Lake Success、New York、美国、11042
- 招聘中
- START New York Long Island LLC
-
接触:
- Pliant Therapeutics Medical Monitor
- 邮箱:clintrials@pliantrx.com
-
-
North Carolina
-
Wilson、North Carolina、美国、27893
- 招聘中
- Carolina Cancer Research Center
-
接触:
- Pliant Therapeutics Medical Monitor
- 邮箱:clintrials@pliantrx.com
-
-
South Dakota
-
Sioux Falls、South Dakota、美国、57105
- 招聘中
- Avera Medical Group
-
接触:
- Pliant Therapeutics Medical Monitor
- 邮箱:clintrials@pliantrx.com
-
-
Tennessee
-
Nashville、Tennessee、美国、37203
- 招聘中
- Tennessee Oncology
-
接触:
- Pliant Therapeutics Medical Monitor
- 邮箱:clintrials@pliantrx.com
-
-
Texas
-
Austin、Texas、美国、78758
- 招聘中
- NEXT Austin
-
接触:
- Pliant Therapeutics Medical Monitor
- 邮箱:clintrials@pliantrx.com
-
Fort Worth、Texas、美国、76104
- 招聘中
- START Center for Clinical Research
-
接触:
- Pliant Therapeutics Medical Monitor
- 邮箱:clintrials@pliantrx.com
-
Houston、Texas、美国、77030
- 招聘中
- University of Texas MD Anderson Cancer Center
-
接触:
- Pliant Therapeutics Medical Monitor
- 邮箱:clintrials@pliantrx.com
-
Houston、Texas、美国、77054
- 招聘中
- NEXT Houston
-
接触:
- Pliant Therapeutics Medical Monitor
- 邮箱:clintrials@pliantrx.com
-
San Antonio、Texas、美国、78229
- 招聘中
- UT Health San Antonio's Mays Cancer Center
-
接触:
- Pliant Therapeutics Medical Monitor
- 邮箱:clintrials@pliantrx.com
-
-
Utah
-
West Valley City、Utah、美国、84119
- 招聘中
- START Mountain Region
-
接触:
- Pliant Therapeutics Medical Monitor
- 邮箱:clintrials@pliantrx.com
-
-
Virginia
-
Fairfax、Virginia、美国、22031
- 招聘中
- Inova Schar Cancer Institute
-
接触:
- Pliant Therapeutics Medical Monitor
- 邮箱:clintrials@pliantrx.com
-
Fairfax、Virginia、美国、22031
- 招聘中
- NEXT Virginia
-
接触:
- Pliant Therapeutics Medical Monitor
- 邮箱:clintrials@pliantrx.com
-
-
Washington
-
Edmonds、Washington、美国、98026
- 招聘中
- Swedish Cancer Institute Medical Oncology
-
接触:
- Pliant Therapeutics Medical Monitor
- 邮箱:clintrials@pliantrx.com
-
-
-
-
Barcelona
-
Barcelona、Barcelona、西班牙、08023
- 招聘中
- Hospital Universitari Quirónsalud (NEXT Barcelona)
-
接触:
- Pliant Therapeutics Medical Monitor
- 邮箱:clintrials@pliantrx.com
-
Barcelona、Barcelona、西班牙、08023
- 招聘中
- START Barcelona - Hospital HM Nou Delfos
-
接触:
- Pliant Therapeutics Medical Monitor
- 邮箱:clintrials@pliantrx.com
-
Barcelona、Barcelona、西班牙、08035
- 招聘中
- Hospital Universitari Vall d'Hebron - VHIO
-
接触:
- Pliant Therapeutics Medical Monitor
- 邮箱:clintrials@pliantrx.com
-
-
La Rioja
-
Logroño、La Rioja、西班牙、26006
- 招聘中
- START Center for Cancer Research - La Rioja
-
接触:
- Pliant Therapeutics Medical Monitor
- 邮箱:clintrials@pliantrx.com
-
-
Madrid
-
Madrid、Madrid、西班牙、28040
- 招聘中
- START Madrid - Hospital Universitario Fundación Jiménez Díaz
-
接触:
- Pliant Therapeutics Medical Monitor
- 邮箱:clintrials@pliantrx.com
-
Madrid、Madrid、西班牙、28050
- 招聘中
- START Madrid - Centro Integral Oncológico Clara Campal
-
接触:
- Pliant Therapeutics Medical Monitor
- 邮箱:clintrials@pliantrx.com
-
-
Pozuelo de Alarcón
-
Madrid、Pozuelo de Alarcón、西班牙、28223
- 招聘中
- University Hospital Quironsalud Madrid (NEXT Madrid)
-
接触:
- Pliant Therapeutics Medical Monitor
- 邮箱:clintrials@pliantrx.com
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Has histologically or cytologically confirmed advanced or metastatic solid tumor
- Have received ≥12 weeks of continuous anti-PD-1 or anti-PD-L1 treatment administered as monotherapy or in combination with other anticancer therapies
- Have demonstrated documented prior clinical benefit, defined as CR or PR at any time during treatment, or SD lasting ≥6 months (Part 2 only)
- Must have subsequently developed radiographic disease progression while receiving anti-PD-1 or anti-PD-L1 treatment or within ≤12 weeks after the last dose of such treatment
- At least 1 measurable lesion, as defined by RECIST v1.1
- Estimated survival of ≥3 months
- Have adequate bone marrow and organ function.
- A female participant is eligible to participate if she is not pregnant, not breastfeeding
Exclusion Criteria:
- Any immune-related medical conditions that would put participants at greater risk when receiving pembrolizumab
- Has a known additional malignancy that is progressing or has required active treatment within the past 2 years
- Has received prior radiotherapy within 2 weeks for palliative bone-directed therapy and 4 weeks for all other radiotherapy
- Has undergone major surgery within 4 weeks prior to the first dose of study treatment or has not adequately recovered from surgery or related complications
- Has a diagnosis of immunodeficiency or use of systemic steroids >10 mg/day
- Has an active autoimmune disease that has required systemic treatment in the past 2 years
- Has known active CNS metastases (brain and/or leptomeningeal metastases)
- Has significant cardiac disease
- Has an active infection requiring systemic therapy (including uncontrolled HIV, Hepatitis B and C)
- Has received a live or live-attenuated vaccine within 30 days or a non-live vaccine within 7 days prior to the first dose of PLN-101095
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:顺序分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Part 1 Dose Escalation - 250 mg BID
Cohort 1 PLN-101095 250 mg BID in combination with pembrolizumab in participants with solid tumors |
PLN-101095 250 mg BID PLN-101095 500 mg BID PLN-101095 1000 mg BID PLN-101095 1000 mg TID PLN-101095 2000 mg BID PLN-101095 Pembrolizumab (KEYTRUDA) 200 mg IV Q3W |
|
实验性的:Part 1 Dose Escalation - 500 mg BID
PLN-101095 500 mg BID in combination with pembrolizumab in participants with solid tumors |
PLN-101095 250 mg BID PLN-101095 500 mg BID PLN-101095 1000 mg BID PLN-101095 1000 mg TID PLN-101095 2000 mg BID PLN-101095 Pembrolizumab (KEYTRUDA) 200 mg IV Q3W |
|
实验性的:Part 1 Dose Escalation - 1000 mg BID
PLN-101095 1000 mg BID in combination with pembrolizumab in participants with solid tumors |
PLN-101095 250 mg BID PLN-101095 500 mg BID PLN-101095 1000 mg BID PLN-101095 1000 mg TID PLN-101095 2000 mg BID PLN-101095 Pembrolizumab (KEYTRUDA) 200 mg IV Q3W |
|
实验性的:Part 1 Dose Escalation - 1000 mg TID
PLN-101095 1000 mg TID in combination with pembrolizumab in participants with solid tumors |
PLN-101095 250 mg BID PLN-101095 500 mg BID PLN-101095 1000 mg BID PLN-101095 1000 mg TID PLN-101095 2000 mg BID PLN-101095 Pembrolizumab (KEYTRUDA) 200 mg IV Q3W |
|
实验性的:Part 1 Dose Escalation - 2000 mg BID
PLN-101095 2000 mg BID in combination with pembrolizumab in participants with solid tumors |
PLN-101095 250 mg BID PLN-101095 500 mg BID PLN-101095 1000 mg BID PLN-101095 1000 mg TID PLN-101095 2000 mg BID PLN-101095 Pembrolizumab (KEYTRUDA) 200 mg IV Q3W |
|
实验性的:Part 2 Dose Expansion - NSCLC
PLN-101095 given as monotherapy and in combination with pembrolizumab in participants with Non-small cell lung cancer (NSCLC) |
PLN-101095 250 mg BID PLN-101095 500 mg BID PLN-101095 1000 mg BID PLN-101095 1000 mg TID PLN-101095 2000 mg BID PLN-101095 Pembrolizumab (KEYTRUDA) 200 mg IV Q3W |
|
实验性的:Part 2 Dose Expansion - ccRCC
PLN-101095 given as monotherapy and in combination with pembrolizumab in participants with Clear cell renal cell carcinoma (ccRCC) |
PLN-101095 250 mg BID PLN-101095 500 mg BID PLN-101095 1000 mg BID PLN-101095 1000 mg TID PLN-101095 2000 mg BID PLN-101095 Pembrolizumab (KEYTRUDA) 200 mg IV Q3W |
|
实验性的:Part 2 Dose Expansion - TMB-high solid tumors
PLN-101095 given as monotherapy and in combination with pembrolizumab in participants with Tumor mutational burden (TMB)-high solid tumors |
PLN-101095 250 mg BID PLN-101095 500 mg BID PLN-101095 1000 mg BID PLN-101095 1000 mg TID PLN-101095 2000 mg BID PLN-101095 Pembrolizumab (KEYTRUDA) 200 mg IV Q3W |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Safety and tolerability of PLN-101095 in combination with pembrolizumab in Parts 1 and 2
大体时间:First dose to 35 days
|
Number of participants with a Dose Limiting Toxicity (DLT) defined as toxicities that meet predefined severity criteria, assess as having a suspected relationship to study drug, unrelated to disease, inter-current illness, or concomitant medications. |
First dose to 35 days
|
|
Safety and tolerability of PLN-101095 in combination with pembrolizumab in Parts 1 and 2
大体时间:Day 1 until 16 weeks after end of study treatment regimen
|
Proportion of participants with treatment-emergent adverse events and serious adverse events. |
Day 1 until 16 weeks after end of study treatment regimen
|
|
Anti-tumor activity of PLN-101095 in combination with pembrolizumab in Part 2
大体时间:First dose to disease progression or death from any cause, whichever occurs first.
|
Proportion of participants achieving confirmed iPR or iCR per iRECIST Version 1.1. |
First dose to disease progression or death from any cause, whichever occurs first.
|
|
Anti-tumor activity of PLN-101095 in combination with pembrolizumab in Part 2
大体时间:First dose to disease progression or death from any cause, whichever occurs first.
|
Proportion of participants who maintain disease control (iCR, iPR or iSD) per iRECIST Version 1.1. |
First dose to disease progression or death from any cause, whichever occurs first.
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
PK of PLN-101095 monotherapy in Parts 1 and 2
大体时间:Day 14, 0 to up to 12 hours
|
Maximum drug concentration (Cmax) |
Day 14, 0 to up to 12 hours
|
|
PK of PLN-101095 monotherapy in Parts 1 and 2
大体时间:Day 14, 0 to up to 12 hours
|
Time to Cmax (Tmax) |
Day 14, 0 to up to 12 hours
|
|
PK of PLN-101095 monotherapy in Parts 1 and 2
大体时间:Day 14, 0 to up to 12 hours
|
Area under the concentration-time curve (AUC0-τ) |
Day 14, 0 to up to 12 hours
|
|
Duration of anti-tumor activity of PLN-101095 in combination with pembrolizumab in Part 2
大体时间:First objective response (CR or PR) to disease progression or death from any cause, whichever occurs first
|
Duration of response (DOR) for objective responders |
First objective response (CR or PR) to disease progression or death from any cause, whichever occurs first
|
|
Duration of anti-tumor activity of PLN-101095 in combination with pembrolizumab in Part 2
大体时间:First dose to progression or death from any cause, whichever occurs first
|
Time on treatment (TOT) for objective responders |
First dose to progression or death from any cause, whichever occurs first
|
合作者和调查者
调查人员
- 研究主任:Pliant Therapeutics Medical Monitor、Pliant Therapeutics, Inc.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他相关的 MeSH 术语
- 泌尿生殖系统疾病
- 生殖器疾病
- 内分泌系统疾病
- 病理过程
- 泌尿生殖系统肿瘤
- 按部位分类的肿瘤
- 肿瘤
- 男性泌尿生殖系统疾病
- 肾脏疾病
- 泌尿系统疾病
- 女性泌尿生殖系统疾病
- 女性泌尿生殖系统疾病和妊娠并发症
- 肠道疾病
- 呼吸道疾病
- 组织学类型的肿瘤
- 消化道肿瘤
- 消化系统肿瘤
- 消化系统疾病
- 肠胃疾病
- 肠道肿瘤
- 直肠疾病
- 子宫疾病
- 生殖器疾病,女性
- 肺部疾病
- 内分泌腺肿瘤
- 肿瘤、腺体和上皮
- 腺癌
- 呼吸道肿瘤
- 胸部肿瘤
- 结肠疾病
- 肿瘤过程
- 肺肿瘤
- 卵巢疾病
- 附件疾病
- 生殖器肿瘤,女性
- 性腺疾病
- 皮肤病
- 乳腺疾病
- 泌尿系肿瘤
- 癌
- 神经外胚层肿瘤
- 肿瘤、生殖细胞和胚胎
- 肿瘤,神经组织
- 肾脏肿瘤
- 癌,支气管癌
- 支气管肿瘤
- 子宫肿瘤
- 神经内分泌肿瘤
- 痣和黑色素瘤
- 皮肤肿瘤
- 乳腺肿瘤
- 肛门疾病
- 直肠肿瘤
- 病理状况、体征和症状
- 皮肤和结缔组织疾病
- 结直肠肿瘤
- 卵巢肿瘤
- 肿瘤转移
- 癌,肾细胞
- 癌,非小细胞肺癌
- 胆管癌
- 黑色素瘤
- 三阴性乳腺肿瘤
- 子宫内膜肿瘤
- 癌,移行细胞
- 肛门肿瘤
- Pembrolizumab
其他研究编号
- PLN-101095-ONC-101
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.